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Abstract
Mutations in rhodopsin, the light-sensitive protein of rod cells, are the most common cause of dominant retinitis pigmentosa
(RP), a type of inherited blindness caused by the dysfunction and death of photoreceptor cells. The P23H mutation, the most
frequent single cause of RP in the USA, causes rhodopsin misfolding and induction of the unfolded protein response (UPR), an
adaptive ER stress response and signalling network that aims to enhance the folding and degradation of misfolded proteins
to restore proteostasis. Prolonged UPR activation, and in particular the PERK branch, can reduce protein synthesis and initiate
cell death through induction of pro-apoptotic pathways. Here, we investigated the effect of pharmacological PERK inhibition
on retinal disease process in the P23H-1 transgenic rat model of retinal degeneration. PERK inhibition with GSK2606414A led
to an inhibition of eIF2a phosphorylation, which correlated with reduced ERG function and decreased photoreceptor survival
at both high and low doses of PERK inhibitor. Additionally, PERK inhibition increased the incidence of inclusion formation in
cultured cells overexpressing P23H rod opsin, and increased rhodopsin aggregation in the P23H-1 rat retina, suggesting
enhanced P23H misfolding and aggregation. In contrast, treatment of P23H-1 rats with an inhibitor of eIF2a phosphatase,
salubrinal, led to improved photoreceptor survival. Collectively, these data suggest the activation of PERK is part of a
protective response to mutant rhodopsin that ultimately limits photoreceptor cell death.
Introduction
Retinitis pigmentosa (RP) is a group of inherited diseases that
cause the progressive dysfunction and degeneration of rod and
cone photoreceptor cells in the retina leading to blindness.
There are currently no effective treatments for RP. Inherited
mutations in rhodopsin, the light sensing protein of rod cells,
are the single most common cause of autosomal dominant RP,
which primarily affect rod cells followed by the secondary loss
of cone cells (1). The majority of mutations are class II muta-
tions and cause protein misfolding, such as P23H, the most
common mutation in the USA (2). The misfolded protein is
retained in the endoplasmic reticulum (ER) and degraded by the
proteasome. If mutant rhodopsin is not efficiently degraded it
can aggregate and form intracellular inclusions, similar to those
found in many other neurodegenerative diseases (3,4). P23H
rhodopsin expression induces the unfolded protein response
(UPR) (5), a signalling network that senses imbalances between
protein synthesis, quality control and degradation in the ER.
The UPR has multiple mechanisms to restore proteostasis by
reducing protein synthesis and upregulating factors that reduce
misfolded proteins in the ER; for example, molecular
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chaperones to stimulate folding and ER-associated degradation
(ERAD) factors to enhance degradation. The UPR has three differ-
ent signalling proteins which are kept in an inactive state by
binding to the ER-chaperone binding immunoglobulin protein
(BiP, HSPA5); the inositol-requiring protein-1 (IRE-1), protein kin-
ase RNA-like ER kinase (PERK), and activating transcription factor
6 (ATF6) (6–8). The PERK branch of the UPR mainly regulates pro-
tein synthesis. Upon ER stress, PERK oligomerises via its cytoplas-
mic domain, autophosphorylates and leads to phosphorylation
of the eukaryotic initiation factor 2a (eIF2a), which activates the
selective translation of activating transcription factor 4 (ATF4)
and transcription of other UPR genes such as C/EBP homologous
protein (CHOP), but also reduces protein synthesis. Protein syn-
thesis is restored when the ATF4 downstream target and specific
phosphatase, GADD34 dephosphorylates eIF2a. Upon failure of
proteostasis restoration, the prolonged activation of UPR can ini-
tiate apoptosis (6,8). Indeed, increased levels of phosphorylated
PERK (p-PERK) and phosphorylated eIF2a (p-eIF2a) have been
found in several neurodegenerative diseases and models, such as
Alzheimer’s disease (AD) (9), Parkinson’s disease (10), amyotro-
phic lateral disease (ALS) (11) and prion diseases (12) directing
future studies on manipulation of the PERK branch. Suppression
of p-eIF2a by genetically deleting PERK in AD mice restored levels
of synaptic proteins and protected against synaptic and memory
dysfunction (13). Furthermore, overexpression of GADD34
reduced eIF2a phosphorylation and increased neuronal survival
in prion-disease mice (12). Moreover, treatment with a selective
inhibitor of PERK, GSK2606414A, increased the survival of prion
disease mice by reducing neuronal cell death (14). This PERK
inhibitor was also protective in a Drosophila model of ALS (15).
The involvement of ER stress and activation of UPR in retinal
degeneration has been examined by several studies [for reviews
(16,17)]. For instance, UPR related genes such as BiP and the proa-
poptotic factor CHOP were found to be altered in P23H transgenic
rats, suggesting that rod opsin misfolding might cause persistent
ER stress that cannot be overcome (5). Additionally, overexpres-
sion of BiP reduced ER stress and protected against retinal degen-
eration in a P23H rat model (18), and ER stress was also observed
in hT17M rhodopsin mice (19). Interestingly, other forms of reti-
nal degeneration, not classically associated with ER protein mis-
folding, have also been reported to induce the UPR (20,21). We
have recently shown that the use of drugs that intervene at dif-
ferent stages of proteostasis imbalance can be used as a thera-
peutic strategy to treat RP. More specifically, treatment with an
Hsp90 inhibitor that induces heat shock protein expression
improved retinal function and survival in P23H transgenic rats
(22). Moreover, we showed that all the three UPR branches were
enhanced by arimoclomol treatment, which also enhances the
heat shock response, and this correlated with protection of pho-
toreceptors in rhodopsin RP models (23).
Therefore, the role of ER stress in the pathogenesis of rhodop-
sin retinal degeneration is unresolved. For example, genetic abla-
tion of CHOP does not protect against rhodopsin RP (24–26),
whereas genetic depletion of ATF4 has been reported to protect
against T17M mutant rhodopsin (27). Here we used a specific
pharmacological inhibitor of PERK to probe the role of PERK acti-
vation in the pathogenesis of P23H related RP. The data show
that PERK inhibition further impairs photoreceptor function and
survival, while it enhances P23H rod opsin misfolding and aggre-
gation. Furthermore, potentiation of eIF2a phosphorylation with
salubrinal delayed photoreceptor degeneration. These data sug-
gest that PERK is part of a protective cellular response to mutant
rhodopsin and is not a good target for this form of rhodopsin RP.
Results
The P23H-1 transgenic rat shows PERK activation (5) and under-
goes fast retinal degeneration with 25% photoreceptor loss by
postnatal day 15 (P15) compared with wild-type (WT) Sprague
Dawley (SD) rats, which provides a rapid and robust model for
the assessment of the ability of drugs to affect photoreceptor
survival (22,23,28,29). GSK2606414A is a potent and selective
inhibitor of PERK, it is functionally active in cells, and inhibits
PERK with a selectivity of>385 fold over other eIF2a kinases and
a panel of 294 kinases, and has excellent central nervous sys-
tem (CNS) penetration following oral dosing (14,30). Therefore,
we tested the ability of GSK2606414A (PERKi) to modify photore-
ceptor degeneration in the P23H-1 transgenic rat.
PERK inhibition reduces visual function in P23H-1 rats
Rats were orally treated daily with a dose of 100 mg/kg PERKi, or
vehicle, as this exceeds the dosing predicted to maximally
inhibit PERK in the brain (14). Specifically, a single oral dose of
100 mg/kg/day PERKi in the rat yielded an area under the curve
(AUC) exposure of 339,000 ng.h/ml (14 days dosing), whereas
50 mg/kg/day orally twice a day (BID) in mouse yielded an AUC
of 13,913 ng.h/ml (5 weeks dosing), which was a fully efficacious
dosing regimen in mouse neuroprotection studies (14).
Treatment was initiated at three weeks of age (P21). At this
stage, there is already retinal degeneration and this corresponds
to a post symptom-onset treatment. The total levels of rhodop-
sin are reduced in this model compared with control SD rat ret-
ina, reflecting the loss of photoreceptor cells (Supplementary
Material, Fig. S1) (31). Rats were monitored daily for body weight
gain and for any adverse effects until the end of the treatment
at P35. Rats tolerated the high dose of PERKi since no adverse
effects were observed throughout the duration of treatment. As
expected, and previously reported (14), PERKi led to a reduction
in the age-related weight gain over the treatment period in the
treated rats (Supplementary Material, Fig. S2A).
Retinal lysates of vehicle and PERKi treated P23H-1 rats were
analysed by immunoblotting to assess whether oral administra-
tion with PERKi successfully inhibited PERK and PERK-mediated
downstream signalling. The expression of mutant P23H rhodop-
sin in P23H-1 rat retina leads to the induction of the UPR (5,23).
Similarly, we observed increased levels of BiP, and p-eIF2a in
P23H-1 vehicle retina compared with SD retina (data not
shown). Treatment with PERKi significantly reduced the phos-
phorylation of eIF2a and the level of PERK and CHOP in P23H-1
retina, whereas the reduction in ATF4 did not reach significance
(Fig. 1A and B). These data confirm access of PERKi to the rat
retina, reduced PERK activity and inhibition of the PERK branch
of the UPR.
Photoreceptor function was assessed by a full field scotopic
electroretinogram (ERG) in dark-adapted rats at P35. Increasing
light intensity correlates with a greater response of photorecep-
tor hyperpolarisation (a-wave), followed by the propagation of
the signal through the retina with subsequent depolarisation
(b-wave). Treatment with PERKi led to lower ERG responses as
both a-wave and b-wave response amplitudes were reduced
compared with vehicle-treated animals (Fig. 1C and D). This
suggests that PERK inhibition impairs the visual function of
P23H-1 rats.
T17M rhodopsin transgenic mice with genetically reduced
levels of ATF4 were recently shown to have delayed photorecep-
tor degeneration (27). Therefore, it is possible that a partial
inhibition of PERK signalling could have different consequences
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for photoreceptor survival from maximal inhibition. Treatment
with PERKi at 10 mg/kg leads to a lower brain exposure to the
inhibitor and a partial neuroprotective response in mice (14);
therefore, we investigated if this lower dose of PERKi would also
affect visual function. The lower dose of PERKi was also well tol-
erated and had a smaller effect on inhibiting body-weight gain
compared with 100 mg/kg dose, suggesting a lower level of sys-
temic PERK inhibition (Supplementary Material, Fig. S2B). The
low dose treatment significantly reduced phosphorylation of
eIF2a and the level of PERK and ATF4 in P23H-1 retina (Fig. 1E
and F), whereas the reduction in CHOP level did not reach signif-
icance. These data suggest that the low dose of PERKi was also
effective at inhibiting the PERK branch of the UPR in the rat ret-
ina. The low dose treatment also reduced both the a-wave and
b-wave ERG responses of P23H-1 rats across a range of light
stimuli (Fig. 1G and H), showing that a lower dose of treatment
also affected visual function.
To investigate if the inhibition of PERK affected the other
branches of the UPR in the retina, the retinal lysates from the
high and low dose treatments were immunoblotted for IRE1 and
phospho-IRE1 (p-IRE1) and ATF6. The data revealed no significant
changes in IRE1 level or phosphorylation (Supplementary
Material, Fig. S3), and no significant change in the level of cleaved
ATF6 (Supplementary Material, Fig. S4). These data suggest that
inhibition of PERK in the P23H-1 rat retina does not lead to a com-
pensatory enhanced activation of either IRE1 or ATF6.
PERK inhibition leads to enhanced photoreceptor cell
death in P23H-1 rats
To investigate whether the reduction in visual function corre-
lated with a reduction in photoreceptor numbers, optical
coherence tomography (OCT) was used to measure the thick-
ness of the outer nuclear layer (ONL), as a marker of photore-
ceptor survival. The measurement of the ONL along the
temporal-nasal meridian is shown in Figure 2A. Treatment
with 100 mg/kg PERKi led to a significant reduction in ONL
thickness across the whole retina (Fig. 2B), suggesting
enhanced photoreceptor cell death. To confirm this observa-
tion, the eyes of vehicle and PERKi treated rats were analysed
by histology (Fig. 2C). The DAPI stained ONL of PERKi treated
retina was noticeably thinner than vehicle-treated P23H-1
retina.
Terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) was used to detect DNA fragmentation and
measure apoptosis in the vehicle and PERKi treated P23H-1 ret-
ina. As expected with the active cell death associated with
P23H expression, there was a high level of TUNEL reactivity in
the vehicle-treated retina, which was further increased on
PERKi treatment (Fig. 2D and E). Activated caspase 3 was not
detectable by immunoblotting (Supplementary Material, Fig.
S5), in agreement with published studies of the P23H-1 retina
(32). In contrast, rod cell death by necroptosis has been
reported in the P23H-1 retina with increased levels of receptor-
interacting serine/threonine-protein kinase 1 (RIP1) (33).
Furthermore, it has been suggested that GSK2606414A can also
inhibit RIP1 (34). Therefore, the level of RIP1 in vehicle and
high dose PERKi treated P23H-1 retina was investigated; the
data show that there was no significant change in the level of
RIP1 (Fig. 2F and G). This suggests that treatment with PERKi
does not have a major effect on RIP1 in the rat retina.
Analyses of the 10 mg/kg treated animals by OCT and histol-
ogy (Fig. 2H–J), confirmed that the ONL was also significantly
reduced at the lower dose of PERKi. Collectively, these data
Figure 1. PERK inhibition reduces visual responses in P23H-1 rats. P23H-1 rats were treated from P21-P35 with either GSK2606414A (PERKi) or vehicle. (A, E)
Representative western blot of retina lysates of P36 P23H-1 rats treated with 100 mg/kg (A) or 10 mg/kg (E) PERKi or vehicle for BiP, PERK, p-eIF2a, eIF2a, ATF4 and CHOP.
GAPDH was used as a loading control. (B, F) Quantification of expression levels of BiP, PERK, p-eIF2a, total eIF2a, ATF4 and CHOP in P23H-1 rats after treatment with
100 mg/kg (B) or 10 mg/kg (F) PERKi. Densitometric analysis was used to calculate the levels of these proteins relative to vehicle; values are mean 6 SEM n 4. (C, D)
Scotopic ERG a-wave (C) and b-wave (D) amplitude results of P23H-1 rats (P36) treated from P21-P35 with either 100 mg/kg PERKi (n¼ 8) or vehicle (n¼6). (G, H) Scotopic
ERG a-wave (G) and b-wave (H) amplitude results of P23H-1 rats (P36) treated from P21-P35 with either 10 mg/kg PERKi (n¼8) or vehicle (n¼6). Values are mean 6 SEM,
*P<0.5, **P< 0.01, Student’s t test.
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show that PERK inhibition compromises visual function and
accelerates photoreceptor loss in the P23H-1 rat.
Prolonging eIF2a phosphorylation enhances P23H-1
photoreceptor survival
As inhibition of PERK activity was detrimental to P23H expressing
photoreceptors, we wanted to test the hypothesis that prolonging
PERK signalling could be protective. Salubrinal is a specific small
molecule inhibitor of eIF2a dephosphorylation (12), and inhibiting
the activity of eIF2a phosphatases can potentiate PERK signalling.
Therefore, we treated P23H-1 rats daily with 1 mg/kg of salubri-
nal, a dose that has previously been shown to affect eIF2a phos-
phorylation in the brain and retina (12,35). Treatment with
salubrinal led to a significant increase in the level of ATF4, and
increased p-eIF2a and CHOP, although this did not reach
statistical significance (Fig. 3A and B). There was no effect of salu-
brinal on visual function as determined by ERG (Fig. 3C and D);
however, there was a small, but significant, increase in ONL
thickness as determined by OCT (Fig. 3E and F), suggesting that
salubrinal can enhance photoreceptor survival in the P23H-1 rat.
PERK inhibition enhances P23H rod opsin aggregation
To investigate the potential mechanisms underlying the accel-
erated retinal degeneration following PERK inhibition, immuno-
histochemistry was used to investigate rhodopsin traffic.
Treatment with either high or low dose PERKi led to an increase
in the co-localisation of rhodopsin with BiP in the ER as deter-
mined by co-localisation analyses (Fig. 4). This suggests that
there is potentially increased rhodopsin ER retention, or
reduced rhodopsin ERAD.
Figure 2. PERK inhibition reduces photoreceptor survival in P23H-1 rats. P23H-1 rats were treated from P21-P35 with either 100 mg/kg (A–G) or 10 mg/kg (H–J) PERKi or
vehicle. (A, H) Spider plot showing P23H-1 ONL thickness at P36 after PERKi (n¼6) or vehicle (n¼6) assessed by OCT. (B, I) Mean ONL thickness across the whole retina
(E). Values are mean 6 SEM. *P< 0.05, ***P<0.001, Student’s t-test. (C, J) Representative images of the retina from P23H-1 (P36) rats treated with vehicle or PERKi.
Cryosections were stained with anti-rhodopsin antibody 1D4 (green), and DAPI (blue) as indicated. (D, E) TUNEL staining in the ONL of P23H-1 rats treated with 100 mg/
kg PERKi or vehicle treated. Arrows highlight positive TUNEL cells. Scale bar 10 mm. (D) Percentage of TUNEL positive cells in the ONL quantified by scoring n¼10 images
each from 2 vehicle-treated rats and 2 PERKi-treated rats (100 mg/kg). Immunoblotting (F) and quantification (G) relative to vehicle of RIP1 immunoreactivity in PERKi
(100mg/kg) and vehicle treated retinal lysates, b-tubulin was used as a loading control. Scale bar 20 mm.
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P23H rhodopsin can aggregate and form intracellular inclu-
sions on heterologous expression in cell culture models (36).
Therefore, we investigated any potential direct effects of PERK
inhibition on rod opsin folding, traffic and aggregation in cell cul-
ture and used the incidence of intracellular inclusions as a surro-
gate marker of protein misfolding and aggregation (23,36).
Treatment with a range of concentrations of PERKi led to a dose
dependent increase in mutant rod opsin inclusions (Fig. 5A and B).
To investigate if PERK inhibition altered rhodopsin aggrega-
tion in vivo, a differential sedimentation assay (22,23,28) was
used to assess the amount of soluble and insoluble rhodopsin
present in P23H-1 retina after manipulation of eIF2a phosphory-
lation. Interestingly, treatment with PERKi did not lead to a dif-
ference in the amount of soluble rhodopsin (Fig. 5C), suggesting
that there was not a major change in rhodopsin degradation fol-
lowing PERK inhibition. In contrast, there was a significant
increase in the amount of insoluble rhodopsin following PERK
inhibition (Fig. 5D). Treatment with salubrinal did not affect
soluble rhodopsin levels, but led to a small non-significant
decrease of insoluble rhodopsin (Fig. 5E and F). These data sug-
gest that PERK activation can reduce mutant rod opsin aggrega-
tion and its inhibition exacerbates mutant rhodopsin ER
retention, misfolding and aggregation.
Discussion
The UPR is an adaptive response that aims to reduce ER stress
through reducing demand (protein translation); increase ER exit
(producing more factors to enable folding); and remove mis-
folded proteins through ERAD; however, sustained activation
can have deleterious effects and lead to cell death. Although the
role of ER stress and activation of the UPR in neurodegeneration
has been extensively investigated, its role in disease progres-
sion remains controversial. The retina offers an excellent
Figure 3. Salubrinal enhances photoreceptor survival in P23H-1 rats. P23H-1 rats were treated from P21-P35 with either 1 mg/kg salubrinal or vehicle. (A) Representative
western blot of retina lysates of P23H-1 rats treated with salubrinal or vehicle for p-eIF2a, eIF2a, ATF4, and CHOP. b-tubulin was used as a loading control. (B)
Quantification of expression levels of p-eIF2a, total eIF2a, PERK ATF4 and CHOP relative to vehicle. (C, D) Scotopic ERG a-wave (C) and b-wave (D) amplitude results of
P23H-1 rats (P36) treated from P21-P35 with either salubrinal (n¼8) or vehicle (n¼9). (E) Spider plot showing P23H-1 ONL thickness at P36 after salubrinal (n¼5) or
vehicle (n¼4) assessed by OCT. (F) Mean ONL thickness across the whole retina Values are mean6 SEM, **P<0.01, Student’s t-test.
5Human Molecular Genetics, 2017, Vol. xx, No. xx |
Downloaded from https://academic.oup.com/hmg/article-abstract/doi/10.1093/hmg/ddx370/4259135
by University College London user
on 13 November 2017
paradigm to study the role of cell stress in neurodegeneration,
due to its accessibility, well-characterised function and the
detailed understanding of genetic causes of retinal degenera-
tion. Furthermore, it can be targeted with systemic, or local
(intravitreal) drug delivery, or gene therapy. In this study, we
used GSK2606414A, a selective inhibitor of PERK (30), to further
investigate the role of this branch of the UPR in retinal degener-
ation associated with misfolded P23H rhodopsin. Our data are
consistent with PERK activation having a protective role against
P23H at these relatively early stages of disease.
We used the well-characterised P23H-1 transgenic rat model,
which has well documented UPR induction (5,23). This model
has 9 copies of a 15 kb genomic fragment containing the mouse
rhodopsin gene with P23H mutated. At one month of age the
P23H allele represents approximately 43% of all the rhodopsin
mRNA in hemizygous rats with the remainder being driven by
the two WT rhodopsin alleles; therefore, this is an overexpres-
sion model expressing almost double the level of rhodopsin
mRNA than a WT rat (31). In contrast, the heterozygous P23H
knock-in mouse, which has a single P23H allele and expresses
P23H mRNA at a level equivalent to one WT allele, appears to
have a different profile of ER stress with lower levels of IRE-1
activation and negligible PERK activation (25,37). Therefore, the
activation of PERK in the P23H rat might be related to the high
levels of expression of the P23H transgene on a background of
two copies of WT rat rhodopsin. This finding questions the
potential direct role for PERK activation in mediating photore-
ceptor cell death at the correct gene dosage. A directly pro-
apoptotic role of PERK also appears unlikely, as CHOP ablation
does not appear to affect P23H mediated photoreceptor cell
death (24,25). The genetic reduction of ATF4, however, protects
against T17M rhodopsin, suggesting a role for the PERK down-
stream target ATF4 in rhodopsin RP cell death (27). This differ-
ence could be due to developmental adaptation to reduced
ATF4 levels leading to an increase in unknown protective fac-
tors, or alternatively different mechanisms of disease for T17M
compared with P23H rhodopsin. However, the loss of CHOP
does not protect the T17M model either (26), suggesting that
any beneficial effects of ATF4 reduction are not mediated
through reducing CHOP. We used a dose of PERKi that had been
shown to provide only partial neuroprotection in the mouse to
test if lower levels of PERK inactivation and reduced ATF4 could
protect the P23H-1 rat. However, rats show a greater exposure
to PERKi on an equivalent dose basis than mouse and therefore,
the level of PERK inhibition in the retina, even at this low dose,
may have been too high to test if partial inhibition could be pro-
tective. Nevertheless, our data provide the first direct evidence
that inhibiting PERK activity is detrimental in P23H mediated
RP. The use of a chemical inhibitor also circumvents any prob-
lems of developmental changes that can confound genetic tar-
geting approaches that are used to study this adaptive
response.
Recently, it was suggested that GSK2606414A, and the
related compound GSK2656157, might not be specific to PERK,
but can also inhibit RIP1 (34). Furthermore, it was recently
shown in the P23H-1 rat model that rod photoreceptors die by
necroptosis via an RIP1/RIP3/DRP1 mechanism, and that rod cell
death could be reduced by treatment with the RIP1 inhibitor
necrostatin 1 s (Nec1s) (33). We investigated whether treatment
with PERKi affected RIP1 and we did not observe any change in
RIP1 levels after PERKi treatment, whereas treatment with
Nec1s has been shown to lead to a strong reduction in RIP1 level
(33). Therefore, if PERKi was mainly acting to inhibit RIP1 in the
retina, it should have a protective effect on rod cell survival and
greater effect on RIP1, which we did not observe. Collectively,
these data further suggest that it is the activity against PERK
that is leading to the enhanced cell death following PERKi
treatment.
Figure 4. PERK inhibition increases rhodopsin ER localisation in P23H-1 rats. P23H-1 rats were treated from P21-P35 with either (A, B) 100 mg/kg or (C, D) 10 mg/kg PERKi
or vehicle. (A, C) Immunohistochemistry of rhodopsin (green) and BiP (red) immunoreactivity in the ONL and inner segment (IS). Scale bar 10mm. (B, D) Rhodopsin-BiP
co-localisation quantified by calculating the Pearson’s and Mander’s co-localisation coefficients using the JaCOP plug-in and ImageJ software, n¼18 images each from
3 vehicle-treated mice and 3 PERKi-treated mice. Values are means6SEM, *P<0.05, ***P<0.001, unpaired two-sided Student’s t test.
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Interestingly, prolonging eIF2a phosphorylation with salu-
brinal had a mild protective effect on the P23H transgenic rat
retina. It was recently reported that salubrinal can reduce
TUNEL reactivity in P23H transgenic mice and P23H knock-in
mice without any WT allele (P23H/-), which both have PERK
activation (35). It is not clear at the moment why the one copy
of the knock-in allele on a null background (P23H/-) would lead
to greater PERK activation than the knock-in allele on a WT
background (P23H/þ), but it could relate to the formation and
traffic of proteins to the specialised ciliary outer segment. P23H
mutant rhodopsin alone cannot mediate the formation of an
outer segment in the absence of any WT allele (38,39), and dis-
ruptions in cilia/outer segment traffic have been reported to
induce the UPR. For example, the loss of BBS12 leads to activa-
tion of PERK and treatment of BBS12 knock-out mice with gua-
nabenz, an inhibitor of eIF2a dephosphorylation, valproic acid
and caspase 12 inhibitor led to enhanced photoreceptor survival
(40). Therefore, potentiating PERK activity appears to be protec-
tive in P23H and ciliopathy models, where PERK is activated. In
the future, it will be interesting to test if enhancing PERK activ-
ity is protective in the absence of any PERK activation. It is also
possible, however, that at later stages of disease prolonged
PERK activation might become detrimental through globally
inhibiting translation, but at the peak of photoreceptor cell
death, the main role appears to be beneficial.
The potential mechanisms of how PERK inhibition might
affect photoreceptor viability were investigated and revealed
that PERK inhibition led to an increase in rhodopsin aggregation
in both cells and the P23H-1 rat retina. We also observed
increased co-localisation of rhodopsin with the ER marker BiP,
suggesting enhanced ER retention or increased expression.
Previously, we have observed that increased PERK activation in
the P23H-1 rat, stimulated by the heat shock protein coinducer
arimoclomol, correlated with a decrease in photoreceptor cell
Figure 5. PERK inhibition increases P23H rhodopsin aggregation. (A, B) SK-N-SH cells were transfected with P23H-GFP rod opsin. Three hours post-transfection and after
2 h recovery in serum cells were either left untreated or treated with 100, 250, 500, 750 mM and 1lM of PERKi for 18 h prior to fixation. (A) Representative confocal
images of P23H-GFP untreated rod opsin or treated with 100mM, 500 mM and 1lM PERKi as indicated. Scale bar 10lm. Magnified cell images are shown in insets. (B)
The incidence of inclusion formation of P23H-GFP in the absence and presence of PERKi at the indicated concentrations was assessed by scoring the percentage of cells
with rod opsin P23H-GFP inclusions in 8 fields of 100 transfected cells. (C–F) Retinae of P23H-1 rats treated from P21-P35 with either 100 mg/kg PERKi (C,D), or salubri-
nal (E, F) or vehicle were analysed by a sedimentation assay. Fractions were immunoblotted with the 1D4 antibody against rhodopsin. Densitometric analysis was used
to calculate the levels of soluble rhodopsin (C,E) relative to the vehicle treated and insoluble rhodopsin (D,F) relative to the vehicle after normalisation to soluble rho-
dopsin. Values are means 6 SEM, n4 (biological replicates). Error bars represent standard error, *P<0.5, **P<0.01, ***P<0.001 Students t-test.
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death and reduced rhodopsin aggregation (23). It is possible that
PERK activation can have dual effects on mutant rhodopsin
expression; to reduce protein synthesis, which lowers the burden
of translating mutant rhodopsin; and to increase the expression
of protective factors, such as BiP, EDEM1, ERdj5 and VCP/p97 that
can reduce mutant rhodopsin aggregation and stimulate ERAD
(41–44). The combination of these effects leads to lower mutant
rhodopsin expression, less ER accumulation and aggregation.
In Drosophila melanogaster, moderate ER stress caused by the
loss of the fly rhodopsin specific chaperone, NinaA, protected pho-
toreceptors from cell death (45) and another study showed that
stimulating ERAD protects against mutant rhodopsin (46).
Similarly, our data support that stimulation rather than inhibition
of the UPR is potentially more beneficial to this type of rhodopsin
RP. This might not be the case for other types of rhodopsin RP or
other forms of retinal degeneration, where induction of the UPR is
a secondary consequence of the disease process, such as those
associated with TDP43 alteration in splicing (15), or PrP aggregation
(12,14). Nonetheless, it appears that in diseases such as P23H-1
rhodopsin RP, where protein misfolding in the ER is part of the pri-
mary disease mechanism, the UPR plays an important role as the
first line of defence against proteotoxic cell stress.
Materials and Methods
Materials
P23H rod opsin-GFP plasmid was as previously described (4). The
mouse monoclonal primary antibody 1D4 (mAb; 1: 1000) against
rod opsin was a gift from Professor Robert Molday (Department of
Biochemistry and Molecular Biology, University of British
Columbia, Canada). Protease inhibitor cocktail (PIC), phosphatase
inhibitor cocktail (PhIC), 4’, 6-diamidino-2-phenylindole dihydro-
chloride (DAPI) and staurosporine were from Merck-Sigma
Hertfordshire, UK) PERK rabbit monoclonal (mAb; 1: 1000), eIF2a
rabbit polyclonal antibodies (pAb; 1: 1000) and cleaved caspase 3
(Asp175) rabbit polyclonal antibodies (pAb; 1: 1000) were from
New England Biolabs (Hitchin, UK). BiP rabbit polyclonal antibody
(pAb; 1: 3000), RIP1 rabbit polyclonal (pAb; 1: 1000), b-tubulin
mouse monoclonal antibody (mAb; 1: 2000) and GAPDH mouse
monoclonal antibodies (mAb; 1: 40000) were from Merck-Sigma.
ATF6 rabbit polyclonal (pAb; 1: 250) and ATF4 rabbit polyclonal
(pAb; 1: 250) were from Santa Cruz (California, USA). CHOP
(GADD113) mouse monoclonal (mAb; 1: 500) was from
Proteintech (Manchester, UK). Phosphorylated eIF2a (pSer51)
(E1F2S1) rabbit polyclonal (pAb; 1: 500) and IRE1a rabbit polyclonal
(pAb; 1: 1000) were from Abcam (Cambridge, UK). Phosphorylated
IRE1a (pSer724) rabbit polyclonal (pAb; 1: 1000) was from Thermo
Fisher Scientific (Massachusetts, USA). Goat anti-rabbit and anti-
mouse secondary antibodies conjugated to horseradish peroxi-
dase were from Pierce (Cramlington, UK). Goat anti-mouse Alexa
Fluor 488 (1: 1000) and goat anti-rabbit Alex Fluor 594 (1: 1000) sec-
ondary antibodies conjugated IgGs (1: 1000) were from Invitrogen
(Paisley, UK). The eIF2a inhibitor Salubrinal (#324895), the lumi-
nata forte and luminata Crescendo HRP substrates were pur-
chased from Millipore (UK) Limited. Lipofectamine and Plus
reagents were purchased from Thermo Fisher Scientific. In situ
cell death detection kit (Fluorescein) was from Sigma (UK).
Animals
All procedures were conducted according to the Home Office (UK)
regulations, under the Animals (Scientific Procedures) Act of 1986,
and with the approval of local UCL-Institute of Ophthalmology,
London, UK ethics committee. The P23H-1 line rats were kindly
provided by Professor Matt LaVail, (University of California, San
Francisco, USA) and crossed with WT Sprague Dawley (SD) rats to
generate hemizygous P23H-1 rats. SD rats were purchased from
Harlan (Blackthorn, UK). All animals were housed under a 12: 12
light dark cycle, with food and water available ad libitum.
GSK2606414A and salubrinal treatment
P23H-1 rats were orally gavaged once daily from P21 to P35 with
10 mg/kg and 100 mg/kg GSK2606414A or vehicle at a volume of
0.2 ml per 50 g of rat or with 1 mg/kg Salubrinal dissolved in
DMSO and then in milk and vehicle (milk). Rats were monitored
daily for any adverse effects and for body weight gain.
Electroretinography (ERG)
At P35, rats were dark-adapted overnight in a ventilated light-
tight box and anaesthetized with Ketamine/Xylazine at 0.2 ml/
100 g intraperitoneally (i.p.). Full-field scotopic ERG was carried
out using the Diagnosys system and Espion software
(Diagnosys, Lowell, MA) under red-light conditions and as previ-
ously described (28). Briefly, simultaneous bilateral recordings
were taken using scotopic ERG protocols. Flash stimuli (10 ms to
1 ms duration, repetition rate 0.2 Hz) were presented via an LED
stimulator (log intensity -5 toþ 1) under scotopic conditions.
ERG responses were collected with the Espion software for anal-
ysis. Statistical analysis was performed using Student’s t test.
Optical coherence tomography (OCT)
Rat retinae were imaged using the Bioptigen Spectral-domain
ophthalmic imaging system (SDOIS) as previously described (28).
Briefly, image acquisition was obtained by using the rectangular
scanning protocol consisting of a 2 mm by 2 mm perimeter with
750 A-scans (lines) and 5 B-scans (frames) with a 60 Frames/B-
scan. The Bioptigen InVivoVue Diver 2.0 was used to enable man-
ual segmentation of the retinal layers and the outer nuclear layer
thickness was measured after exporting results from Diver to
Excel. Statistical analysis was performed using Student’s t test.
SDS-PAGE and western blot
Retinae were extracted and lysed with ice-cold RIPA buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1%
SDS, 0.05% sodium deoxycholate) containing 2% (v/v) mamma-
lian protease inhibitor cocktail (PIC) 2% (v/v) mammalian phos-
phatase inhibitor cocktail. Retina lysates were sonicated for 2 
30 s, centrifuged for 15 min at 12 000 g and at 4 C and diluted in
5 sodium dodecyl sulphate (SDS) sample loading [0.0625 M Tris
pH 6.8, 2% (w/v) SDS, 30% (v/v) glycerol, 20% (v/v) b-mercaptoe-
thanol] to a final concentration of 1. Samples for rod opsin were
not denatured whereas samples for all the other antibodies were
heated at 95 C for 5 min before they were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and western blot.
Proteins were transferred to nitrocellulose with 25 mM Tris,
192 mM Glycine, 0.01% SDS (w/v) and 20% (v/v) Methanol. To pre-
vent non-specific binding, membranes were blocked at 4 C with
either 5% (w/v) Marvel Milk in PBS with 0.1% (v/v) Tween buffer or
and 5% (w/v) BSA in TBS with 0.1% (v/v) Tween buffer.
Immunodetection of proteins of interest was carried out using
the primary and secondary antibodies described in Materials sec-
tion. Proteins were detected using the Luminata Forte and
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Luminata Crescendo HRP substrate kits. Rhodopsin sedimenta-
tion assay was performed as described previously (22,23,28).
Immunohistochemistry
Eyes were dissected and fixed overnight in 4% paraformaldehyde
at 4 C following by cryoprotection with 30% sucrose in PBS. Eyes
were then frozen and cryosectioned as described (22). Eye sec-
tions were incubated in blocking buffer [3% bovine serum albu-
min (BSA) and 10% normal goat serum in PBS] for 1 h at room
temperature before incubation with primary antibodies, as indi-
cated. DAPI staining was used for nuclei visualisation. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay was performed using an in situ cell death detection kit
(Fluorescein) following the manufacturer’s instructions.
Cell transfection, drug treatments and
immunofluorescence
SK-N-SH human neuroblastoma cells were maintained and
transfected essentially as previously described (41). Three hours
after transfection and 2 h after recovery in serum, cells were
either left untreated or treated with 100 nM to up to 1 lM
GSK2606414A for 18 h. Immunofluorescence was performed as
previously described (44).
Image analysis
Image acquisition of cells and retina was obtained using Carl Zeiss
LSM700 laser-scanning confocal microscope. Images were exported
from Zen 2009 software and prepared using Adobe Photoshop and
Illustrator CS4. Cell morphology studies were scored as previously
described (36). The Pearson’s and Mander’s co-localisation co-
efficients in cells co-stained using Rho-1D4 and anti-BiP antibodies
were measured with JaCOP plug-in and ImageJ software.
Supplementary Material
Supplementary Material is available at HMG online.
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